RVPMEDIUM SIGNALRISK10-K

RVP faced significant tariff volatility throughout 2025 that impaired cost predictability and business operations, while the company's balance sheet contracted amid declining cash position.

The shift from specific tariff disclosures to broader language about "fluctuating" tariff rates suggests RVP encountered more complex and unpredictable trade policy impacts than previously experienced. The removal of COVID-related revenue tailwinds indicates the company is navigating a post-pandemic normalization while simultaneously managing new trade headwinds that directly affect their import-dependent business model.

Comparing 2026-03-27 vs 2025-03-28View on EDGAR →
FINANCIAL ANALYSIS

RVP generated solid revenue growth of 16% while meaningfully improving operating cash flow performance, though both remained challenged by the tariff environment. However, the balance sheet shows concerning contraction with cash declining 39% to just $2.6M, total assets shrinking 11%, and stockholders' equity falling 15% despite increased share buybacks of $7.6M. The combination of a weakened balance sheet position and heightened tariff uncertainty creates meaningful near-term financial flexibility concerns.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
+68.8%
$853K$1.4M

Capital expenditure jumped 68.8% — major investment cycle underway; assess returns on deployment.

Share Buybacks
Cash Flow
+44.5%
$5.3M$7.6M

Share repurchases increased 44.5% — management returning capital, signals confidence in intrinsic value.

Cash & Equivalents
Balance Sheet
-38.9%
$4.2M$2.6M

Cash declined 38.9% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Operating Cash Flow
Cash Flow
+38.9%
-$11.6M-$7.1M

Operating cash flow surged 38.9% — exceptional cash generation, highest quality earnings signal.

Total Debt
Balance Sheet
-27.3%
$1.2M$896K

Debt reduced 27.3% — deleveraging strengthens balance sheet and reduces financial risk.

Revenue
P&L
+15.8%
$33.0M$38.3M

Revenue growing 15.8% — solid top-line momentum, watch margins for quality of growth.

Stockholders Equity
Balance Sheet
-14.7%
$87.2M$74.4M

Equity decreased 14.7% — buybacks or losses reducing book value, monitor solvency ratios.

Current Assets
Balance Sheet
-13.9%
$73.3M$63.1M

Current assets declined 13.9% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-11.3%
$160.7M$142.6M

Total assets contracted 11.3% — asset sales, write-downs, or balance sheet optimization underway.

Inventory
Balance Sheet
-10.4%
$19.2M$17.2M

Inventory reduced 10.4% — lean inventory management or demand outpacing supply.

LANGUAGE CHANGES
NEW — 2026-03-27
PRIOR — 2025-03-28
ADDED
As of March 9, 2026, there were 29,937,159 shares of our Common Stock outstanding, excluding treasury shares.
Beginning in early 2025 and throughout much of the year, additional widespread tariffs were imposed on most products imported into the U.S.
citing authority under the International Emergency Economic Powers Act ( IEEPA ).
Those tariffs were in addition to the Section 301 tariffs which existed at the time.
Throughout 2025, the prevailing tariff rates on various products and certain countries of origin, including many of our products, fluctuated greatly.
+7 more — sign up free →
REMOVED
As of March 10, 2025, there were 29,937,159 shares of our Common Stock outstanding, excluding treasury shares.
Our syringes are well-suited for administering vaccinations and our revenues materially increased in 2020-2021 due to COVID-19 vaccination demand.
government for vaccinations wound down in the first quarter of 2022, although international vaccination demand positively and materially impacted sales throughout 2022 and the first quarter of 2023.
In September 2024, a new 100% tariff on syringes and needles imported from China became effective.
Additionally, effective February 4th and March 4th of 2025, tariffs on Chinese imports were increased by an aggregate total of 20%.
+7 more — sign up free →
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →